Also, low-dose cyclophosphamide is used to improve Daratumumab-mediated ADCP against tumor cells, probably mediated by increased expression of FcγR on macrophages and reduced CD47 levels on tumor cells 78. The gene discussed is CD47; the disease is neoplasm.